Technical Data
Matrix Gla Protein (MGP, Cell growth-inhibiting gene 36 protein, GIG36, Matrix Gla protein, MGLAP, NTI )
Suitable for use in Immunohistochemistry Other applications not tested.

Recommended Dilution:
Immunohistochemistry: 25ug/ml
Optimal dilutions to be determined by the researcher.

Storage and Stability:
Lyophilized powder may be stored at 4C for short-term only. Reconstitute to nominal volume by adding sterile 40-50% glycerol and store at -20C. Reconstituted product is stable for 12 months at -20C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.
10ug-20CBlue IceHumanMouse
Synthetic human Matrix Gla Protein (aa 3-15) (SHESMESYELNPF)
Supplied as a lyophilized powder in PBS, pH 7.2. Reconstitute in ddH2O.
Recognizes human matrix Gla protein caboxylated, human matrix Gla protein non-caboxylated
Intended for research use only. Not for use in human, therapeutic, or diagnostic applications.
1. Spronk HM, Soute BA, Schurgers LJ, Cleutjens JP, Thijssen HH, De Mey JG, Vermeer C. Matrix Gla protein accumulates at the border of regions of calcification and normal tissue in the media of the arterial vessel wall. Biochem Biophys Res Commun 2001;289:485-90. 2. Schurgers LJ, Dissel PE, Spronk HM, Soute BA, Dhore CR, Cleutjens JP, Vermeer C. Role of vitamin K and vitamin K-dependent proteins in vascular calcification. Z Kardiol 2001;90 Suppl 3:57-63. 3. Dhore CR, Cleutjens JP, Lutgens E, Cleutjens KB, Geusens PP, Kitslaar PJ et al. Differential expression of bone matrix regulatory proteins in human atherosclerotic plaques. Arterioscler Thromb Vasc Biol 2001;21:1998-2003. 4. Farzaneh-Far A, Davies JD, Braam LA, Spronk HM, Proudfoot D, Chan SW et al. A polymorphism of the human matrix gamma-carboxyglutamic acid protein promoter alters binding of an activating protein-1 complex and is associated with altered transcription and serum levels. J Biol Chem